Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GUB014295
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Modular Medical Announces Proof-of-Concept for Personalized Metabolic Therapy
Details : GUB014295 is a long acting GLP-1 analog injectables, it is being developed for the treatment of patients with overweight.
Product Name : GUB014295
Product Type : Peptide
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : GUB014295
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
Details : The insulin delivery technology company with the first FDA-cleared patch pump, designed specifically to target all adult "almost-pumpers," offers a user-friendly and affordable solution for obesity.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Insulin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable